뒤로
Jupiter Neurosciences Inc(JUNS) 가격
JUNS 주가 차트
JUNS 수입
Jupiter Neurosciences Inc
$0.58
-4.5%
$-0.02
오늘 기준:Feb 11, 10:25:21 GMT-5
최신 수익 결과: Q3 '25
보고됨: 2025-11-14
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
JUNS의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Jupiter Neurosciences Inc JUNS의 지난 분기 매출 실적은 어땠나요?
Jupiter Neurosciences Inc의 매출 추정치는 얼마인가요?
Jupiter Neurosciences Inc의 수익 품질 점수는 얼마인가요?
Jupiter Neurosciences Inc는 언제 수익을 보고하나요?
Jupiter Neurosciences Inc의 예상 수익은 얼마인가요?
Jupiter Neurosciences Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.6147
시가
$0.586
일일 범위
$0.586 - $0.5962
52주 범위
$0.48 - $3.33
거래량
3.3K
평균 거래량
275.2K
EPS(TTM)
-0.18
배당수익률
--
시가총액
$20.2M
JUNS란 무엇인가요?
Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. The company has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.